Rep. Thomas H. Kean, Jr. Sells Shares of Becton, Dickinson and Company (NYSE:BDX)

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Becton, Dickinson and Company (NYSE:BDX). In a filing disclosed on June 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Becton, Dickinson and Company stock on May 21st. The trade occurred in the Representative’s “KEAN FAMILY PARTNERSHIP” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Check Point Software Technologies (NASDAQ:CHKP) on 6/1/2026.
• Purchased $1,001 – $15,000 in shares of EQT (NYSE:EQT) on 6/1/2026.
• Purchased $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 5/14/2026.
• Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 4/29/2026.
• Sold $1,001 – $15,000 in shares of Take-Two Interactive Software (NASDAQ:TTWO) on 4/21/2026.
• Sold $1,001 – $15,000 in shares of nVent Electric (NYSE:NVT) on 4/15/2026.
• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 4/14/2026.
• Sold $1,001 – $15,000 in shares of First Citizens BancShares (NASDAQ:FCNCA) on 4/14/2026.
• Purchased $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 3/31/2026.
• Sold $15,001 – $50,000 in shares of S&P Global (NYSE:SPGI) on 3/26/2026.

Becton, Dickinson and Company Stock Up 0.0%

Shares of Becton, Dickinson and Company stock traded up $0.02 on Friday, hitting $158.10. 2,036,087 shares of the company’s stock traded hands, compared to its average volume of 2,812,766. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The stock has a market cap of $43.56 billion, a P/E ratio of 40.02, a PEG ratio of 11.19 and a beta of 0.21. The firm’s 50-day moving average is $147.98 and its 200 day moving average is $169.33.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 12.62 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were issued a dividend of $1.05 per share. The ex-dividend date was Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.7%. Becton, Dickinson and Company’s payout ratio is currently 106.33%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Piper Sandler lowered their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Finally, Argus lowered their price objective on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $181.00.

Institutional Trading of Becton, Dickinson and Company

Hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc raised its holdings in shares of Becton, Dickinson and Company by 37.4% during the second quarter. Versant Capital Management Inc now owns 914 shares of the medical instruments supplier’s stock valued at $138,000 after buying an additional 249 shares during the last quarter. CX Institutional grew its holdings in Becton, Dickinson and Company by 56.0% in the 2nd quarter. CX Institutional now owns 1,315 shares of the medical instruments supplier’s stock worth $199,000 after buying an additional 472 shares in the last quarter. SWP Investment Management LLC increased its position in Becton, Dickinson and Company by 52.5% in the 2nd quarter. SWP Investment Management LLC now owns 16,200 shares of the medical instruments supplier’s stock valued at $2,452,000 after acquiring an additional 5,575 shares during the period. Eastern Bank raised its stake in Becton, Dickinson and Company by 11.0% during the 2nd quarter. Eastern Bank now owns 2,875 shares of the medical instruments supplier’s stock valued at $435,000 after acquiring an additional 286 shares in the last quarter. Finally, Ravenstone Capital Management Inc. acquired a new position in Becton, Dickinson and Company during the 1st quarter worth $7,465,000. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,188 shares of company stock worth $765,120 over the last three months. Corporate insiders own 0.40% of the company’s stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.